Coloma Jason V's Form 4 filing
Maze Therapeutics, Inc. (MAZE) · filed May 27, 2026
- Accession no.
- 0001676170-26-000007
- Filed
- May 27, 2026
- Trade date
- May 22-26, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $847.2K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Coloma Jason VCIK 0001676170 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Common Stock | SSaleDisposed | −4,504 | $26.00 | −$117,104 | 376,569 | Indirect | |
| May 22, 2026 | Common Stock | SSaleDisposed | −2,478 | $26.00 | −$64,428 | 28,523 | Indirect | |
| May 26, 2026 | Common Stock | SSaleDisposed | −25,582 | $26.02 | −$665,643.64 | 350,987 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.